Literature DB >> 6206345

Precapillary vessels: effects of the sympathetic nervous system and of catecholamines.

V Alabaster, M Davey.   

Abstract

The study of receptor-operated control mechanisms involved in adrenergic transmission in the blood vessel wall has substantially advanced the understanding of the factors involved in the maintenance of arteriolar tone. As a result of this work, alpha-adrenoreceptors have been divided into two major subtypes termed alpha 1- and alpha 2-adrenoreceptors. Initially, the term alpha 1 was proposed as a synonym for the postjunctional alpha-adrenoreceptor. There is now a large body of evidence for the existence of postjunctional alpha-adrenoreceptors mediating the contraction of vascular smooth muscles that are resistant to blockade by the alpha 1-adrenoreceptor antagonist prazosin, but are blocked by alpha 2-antagonists and can be activated by selective alpha 2-agonists but not by selective alpha 1-agonists. The physiological significance of postjunctional alpha 2-adrenoreceptors is discussed in respect to factors such as their role in blood pressure control and of whether they are innervated or not, and the differences in contractile responses and in the postreceptor mechanisms involved in stimulation-contraction coupling following activation of each receptor subtype are reviewed. Although the situation is complex, on balance the data are compatible with the view that alpha 2-adrenoreceptor-mediated responses in vascular smooth muscle are more dependent on the physiological environment than are responses mediated by alpha 1-adrenoceptors. Thus, although postjunctional alpha 2-adrenoreceptors can be involved in sympathetic nerve transmission, they appear largely to fulfill a humoral role in vascular smooth muscle closely allied to the prevailing conditions, whereas alpha 1-adrenoreceptors are primarily involved in sympathetic neurotransmission, independent of local environmental conditions.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6206345

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  8 in total

1.  Topical combinations to treat microvascular dysfunction of chronic postischemia pain.

Authors:  André Laferrière; Rachid Abaji; Cheng-Yu Mark Tsai; J Vaigunda Ragavendran; Terence J Coderre
Journal:  Anesth Analg       Date:  2014-04       Impact factor: 5.108

2.  Effects of alpha-adrenoceptor antagonists on striated muscle microcirculation of conscious rats.

Authors:  M W Messing; H van Essen; H A Struyker Boudier
Journal:  Drugs       Date:  1990       Impact factor: 9.546

3.  Responses to noradrenaline in human subcutaneous resistance arteries are mediated by both alpha 1- and alpha 2-adrenoceptors.

Authors:  H Nielsen; F V Mortensen; M J Mulvany
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

4.  Adrenergic stimulation of the rat mesenteric vascular bed: a combined micro- and macrocirculatory study.

Authors:  L M Le Noble; G J Tangelder; D W Slaaf; J F Smits; H A Struyker-Boudier
Journal:  Pflugers Arch       Date:  1987-10       Impact factor: 3.657

5.  Lack of involvement of alpha-adrenoceptors in sympathetic neural vasoconstriction in the hindquarters of the rabbit.

Authors:  G D Hirst; M J Lew
Journal:  Br J Pharmacol       Date:  1987-01       Impact factor: 8.739

6.  Causative role of coronary microvessels for the development and progression of chronic myocardial lesions in spontaneously hypertensive rats (SHR).

Authors:  H J Herrmann; P Mühlig
Journal:  Basic Res Cardiol       Date:  1992 Sep-Oct       Impact factor: 17.165

7.  Comparison of potency of alpha 2-adrenoceptor antagonists in vitro: evidence for heterogeneity of alpha 2-adrenoceptors.

Authors:  V A Alabaster; R F Keir; C J Peters
Journal:  Br J Pharmacol       Date:  1986-07       Impact factor: 8.739

8.  The alpha 1-adrenoceptor antagonist profile of doxazosin: preclinical pharmacology.

Authors:  V A Alabaster; M J Davey
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.